[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370308-105":59,"doc-detail-370308-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","development-of-attenuated-orf-virus-as-a-safe-oncolytic-viral-vector-for-nasopharyngeal-carcinoma-treatment","Development of attenuated Orf virus as a safe oncolytic viral vector for nasopharyngeal carcinoma treatment","","Orf virus (ORFV) is explored as a promising oncolytic viral vector for treating nasopharyngeal carcinoma (NPC), leveraging its unique properties and recent evidence of antitumor activity. The study compares wild-type ORFV with recombinant attenuated ORFVs lacking virulence factors VEGF or CBP, assessing infection, cell death mechanisms, and immune modulation. In vitro results show pyroptosis driven by GSDME cleavage, altered survival signaling (FAK/AKT), and enhanced NK recruitment and cytotoxicity. Xenograft experiments further demonstrate strong tumor growth inhibition for the CBP-deleted variant, supporting a safer therapeutic option.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-of-attenuated-orf-virus-as-a-safe-oncolytic-viral-vector-for-nasopharyngeal-carcinoma-treatment/370308/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-of-attenuated-orf-virus-as-a-safe-oncolytic-viral-vector-for-nasopharyngeal-carcinoma-treatment/370308.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of this research on ORFV for nasopharyngeal carcinoma?","Question",{"text":112,"@type":113},"To evaluate whether wild-type ORFV and recombinant, virulence-factor-deleted ORFVs can kill NPC cells and enhance anti-tumor immune responses in a safer way.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the oncolytic effects and cell death pathways assessed in the study?",{"text":117,"@type":113},"NPC cell lines were infected with wild-type ORFV and deletion mutants, and cell death was evaluated with emphasis on pyroptosis, monitored via GSDME cleavage, alongside signaling pathway analyses such as FAK and AKT.",{"name":119,"@type":110,"acceptedAnswer":120},"What immune-related effects were observed after ORFV infection?",{"text":121,"@type":113},"ORFV infection increased natural killer (NK) cell recruitment and boosted NK cell-mediated cytotoxicity against infected NPC cells.",{"name":123,"@type":110,"acceptedAnswer":124},"Which ORFV variant showed stronger antitumor activity in vivo?",{"text":125,"@type":113},"In the HK1 xenograft mouse model, the CBP-deleted ORFV significantly inhibited tumor growth compared with other conditions described.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},370308,1791216716,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Yamada et al. Virology Journal (2025) 22:50 [https://doi.org/10.1186/s12985-025-02672-3](https://doi.org/10.1186/s12985-025-02672-3)  \nVirology Journal  \nRESEARCH Open Access  \nDevelopment of attenuated Orf virus as a safe  oncolytic viral vector for nasopharyngeal carcinoma treatment  \nYumiko Yamada 1, Yu-Chih Wang2, Hao-Ping Liu3, Greg Ryan Gerongano4, Ching-Yu Tseng 1, Shu-Chen Liu5, GuanRu Liao 1, Chao-Chin Chang 1, Jiunn-Wang Liao2, Mei-Lin Wang6, Yuan-Yen Chang6, Fong-Yuan Lin7 and Wei-Li Hsu 1,8*  \nAbstract  \nBackground Orf virus (ORFV) is gaining attention as a promising viral vector for cancer therapy because of its unique properties. Recent studies have shown that ORFV could be effective against various cancers, particularly nasopharyngeal carcinoma. This research explores the ability of wild-type ORFV and recombinant ORFVs, which lack specific virulence factors, to kill NPC cells and modulate the immune response.  \nMethods Two NPC cell lines, HK1 (from Hong Kong) and TW02 (from Taiwan), were infected with wild-type ORFV and two recombinant ORFVs lacking either vascular endothelial growth factor (VEGF) or chemokine binding protein (CBP) virulence factors. The oncolytic effects were evaluated by assessing cell death pathways, particularly pyroptosis, which was monitored through the cleavage of gasdermin E (GSDME) . The activation of survival pathways, such as focal adhesion kinase (FAK) and AKT, was also analyzed. In addition, the influence of ORFV infection on natural killer (NK) cell recruitment and cytotoxicity was investigated. In vivo experiments were conducted in a xenograft mouse model in which HK1 tumors were used to evaluate the antitumor activity of wild-type ORFV and two deletion-mutant ORFVs. Results Wild-type ORFV effectively killed NPC cells, especially HK1 cells. The recombinant ORFVs, despite being attenuated by the loss of VEGF or CBP, retained the ability to infect and cause NPC cell death, with the CBP-deleted virus showing notable effectiveness in HK1 cells. Early ORFV infection led to pyroptosis via GSDME cleavage, causing cell detachment and a reduction in FAK and AKT activation. ORFV also enhanced NK cell recruitment and boosted NK cell-mediated cytotoxicity in infected NPC cells. In the HK1 xenograft model, CBP-deleted ORFV significantly inhibited tumor growth.  \nConclusion ORFV, particularly the wild-type and CBP-deleted variants, has significant potential as an oncolytic viral vector for NPC therapy. It induces cell death via pyroptosis and enhances immune-mediated tumor cell destruction through NK cells. The attenuated CBP-deleted ORFV offers a safer and effective option for cancer treatment, making ita promising candidate for future therapeutic applications.  \nKeywords Oncolytic-attenuated ORFV, Nasopharyngeal carcinoma, NK cells, Cell death, Xenograft model  \n*Correspondence:  \nWei-Li Hsu[wlhsu@dragon.nchu.edu.tw](wlhsu@dragon.nchu.edu.tw)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [","cbCaih6TnXy8mrnA","https://ap.wps.com/l/cbCaih6TnXy8mrnA","pdf",2968915,18,"English","# Introduction\n# Methods\n# Results\n# Conclusion\n# Keywords","[{\"question\":\"What is the main goal of this research on ORFV for nasopharyngeal carcinoma?\",\"answer\":\"To evaluate whether wild-type ORFV and recombinant, virulence-factor-deleted ORFVs can kill NPC cells and enhance anti-tumor immune responses in a safer way.\"},{\"question\":\"How were the oncolytic effects and cell death pathways assessed in the study?\",\"answer\":\"NPC cell lines were infected with wild-type ORFV and deletion mutants, and cell death was evaluated with emphasis on pyroptosis, monitored via GSDME cleavage, alongside signaling pathway analyses such as FAK and AKT.\"},{\"question\":\"What immune-related effects were observed after ORFV infection?\",\"answer\":\"ORFV infection increased natural killer (NK) cell recruitment and boosted NK cell-mediated cytotoxicity against infected NPC cells.\"},{\"question\":\"Which ORFV variant showed stronger antitumor activity in vivo?\",\"answer\":\"In the HK1 xenograft mouse model, the CBP-deleted ORFV significantly inhibited tumor growth compared with other conditions described.\"}]","Development of attenuated Orf virus as a safe oncolytic viral vector for nasopharyngeal carcinoma treatment | PDF",1790187911,45,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51f8fce06814775b44efab87328c4d2e.webp",983,1310,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49a408c048054ac74c52817def1e6bfe.webp",982,1309,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/56506242ad6f54af6c9f785af06c39c3.webp",981,1308,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/54c9c61736907e6bbf4c02ccdf3a6ddb.webp",980,1306]